In addition, the researchers successfully used CRISPR-Cas9 base-editing technology to introduce the E545K mutation (one of the most common PIK3CA mutations), which opens up new opportunities for scientists to use patient-derived 3D models to search for and validate potential biomarkers of HNSCC response to therapy [160]. Here, PIK3CA is linked to head and neck squamous cell carcinoma.